ARS Pharmaceuticals, Inc (SPRY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ARS Pharmaceuticals, Inc (SPRY) has a cash flow conversion efficiency ratio of -0.381x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.48 Million) by net assets ($114.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ARS Pharmaceuticals, Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how ARS Pharmaceuticals, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SPRY total liabilities for a breakdown of total debt and financial obligations.
ARS Pharmaceuticals, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ARS Pharmaceuticals, Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Black Diamond Group Limited
TO:BDI
|
0.046x |
|
Zhongyin Babi Food Co. Ltd.
SHG:605338
|
0.107x |
|
Zhangjiagang Furui Special Equip
SHE:300228
|
0.106x |
|
XPLR Infrastructure LP Unit
NYSE:XIFR
|
-0.011x |
|
Besalco Sa
SN:BESALCO
|
0.062x |
|
Quanex Building Products
NYSE:NX
|
-0.028x |
|
Wecome Intelligent Manufacturing Co. Ltd.
SHG:603070
|
N/A |
|
MetroCity Bankshares
NASDAQ:MCBS
|
0.030x |
Annual Cash Flow Conversion Efficiency for ARS Pharmaceuticals, Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of ARS Pharmaceuticals, Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see market value of ARS Pharmaceuticals, Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $114.26 Million | $-170.87 Million | -1.495x | -2934.56% |
| 2024-12-31 | $256.80 Million | $13.55 Million | 0.053x | +120.54% |
| 2023-12-31 | $230.76 Million | $-59.27 Million | -0.257x | -74.87% |
| 2022-12-31 | $272.89 Million | $-40.08 Million | -0.147x | -126.15% |
| 2021-12-31 | $-31.27 Million | $-17.56 Million | 0.562x | +187.00% |
| 2020-12-31 | $-14.05 Million | $9.07 Million | -0.646x | -119.14% |
| 2019-12-31 | $-5.60 Million | $-18.90 Million | 3.373x | +463.71% |
| 2018-12-31 | $18.20 Million | $-16.88 Million | -0.927x | -- |
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is … Read more